Karyopharm - oncology









































































Companies with ADC programs is very broad. Merck is a great fit with the EC opportunity and their presence in Women's cancer along with the positive results in combo with Ovarian cancer seen in early stage. Incyte is another opportunity as KPTI is positioning themselves well with the PH2 combo trials with several other products in MF along with their excellent Ph1 seli + Rux trial. GSK, GILD, ABBV are also potential good options.